Biograph VisionSee a whole new world of precision.

Normal brain study with sharp delineation of functioning cortex and increased contrast between cortex and white matter.

Examination protocol
Biograph Vision, 5.4 mCi (200 MBq)¹⁸F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.

Fluoro-dihydrotestosterone (¹⁸F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after^{[a] 18} FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.

Clinical detail
A 73-year-old male with prostate cancer treated with brachytherapy presented with biochemical relapse. The patient underwent PET/CT study following injection of androgen receptor imaging agent ¹⁸F –dihydrotestosterone (¹⁸F-FDHT) in order to assess presence of androgen receptor positive recurrence. PET/CT was performed on Biograph Vision™. Images showed tracer within cardiac and vascular blood pool as well as in the liver. Significant clearance of tracer through the biliary tract and gall bladder, kidneys, and intestines is visualized. No well defined focal uptake suggestive of androgen receptor-avid metastatic lesions is visualized, although primary prostate bed showed significant uptake on higher intensity images. Sharp delineation of vascular structures, especially cavernous and sigmoid sinuses as well as carotid and subclavian vessels reflect the high overall image quality and low noise level in the Biograph Vision images.

Fluoro-dihydrotestosterone (¹⁸F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after^{[a] 18} FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.

Examination protocol
Biograph Vision , 5.4 mCi (200 MBq)¹⁸F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.

_{^[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens Healthineers does not make any claims regarding its use.}

Fluoro-dihydrotestosterone (¹⁸F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after^{[a] 18} FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.

Examination protocol
Biograph Vision , 5.4 mCi (200 MBq)¹⁸F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.

_{^[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens Healthineers does not make any claims regarding its use.}

Fluoro-dihydrotestosterone (¹⁸F FDHT) PET/CT study in a patient with prostate cancer with biochemical relapse. Sequential whole-body dynamic FlowMotion™ acquisitions shortly after^{[a] 18} FDHT administration demonstrates blood pool activity within heart and major vessels as well as tracer clearance through liver, kidneys, and intestine.

Examination protocol
Biograph Vision , 5.4 mCi (200 MBq)¹⁸F FDG, 51 minutes post-injection delay. CT: 80 kV, 30 eff mAs. 128 x 0.6 mm collimation, PET: 15 minutes total scan time 440 x 440 matrix.

_{^[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.}

⁶⁸Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.

Clinical detail
A 78-year-old male with primary prostate cancer underwent ⁶⁸Ga-PSMA PET/CT initial staging. PET/CT was performed on Biograph Vision™.  The images showed high tracer uptake in kidneys, salivary glands, and bladder, which are at physiologically normal levels. The liver, spleen, and intestines also show lower but normal levels of uptake as well. There is also focal hypermetabolism in the prostate reflecting primary tumor and the small hypermetabolic right external iliac lymph node is suggestive of solitary nodal metastases. No other PSMA-avid metastatic lesions are visualized. Sharply delineated renal, salivary gland, bladder, and intestinal margins reflect the high overall image quality and low background noise level in the Biograph Vision images.

⁶⁸Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.

Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) ⁶⁸Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.

_{^[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.}

Visualization of 7 mm lymph node metastases on ⁶⁸Ga-PSMA^[a] evaluation of primary prostate cancer
⁶⁸Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.

Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) ⁶⁸Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.

_{^[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.}

Visualization of 7 mm lymph node metastases on ⁶⁸Ga-PSMA^[a] evaluation of primary prostate cancer
⁶⁸Ga-PSMA PET/CT in a patient with primary prostate cancer shows PSMA-avid primary tumor along with small PSMA-avid right external iliac lymph node metastases. Uptake in the kidneys, salivary gland, liver, intestine, and urinary bladder are within physiological limits.

Examination protocol
Biograph Vision, 2.7 mCi (100 MBq) ⁶⁸Ga-PSMA, 1 hour 45 minutes post-injection delay. CT: 100 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 220 x 220 matrix.

_{^[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.}

Hypermetabolic right obturator and liver metastases visualized with high contrast on ¹⁸F FDG PET/CT in a patient with operated ovarian carcinoma.

Clinical detail
A 49-year-old woman with a history of operated ovarian carcinoma with suspected recurrence underwent ¹⁸F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision™. The images showed hypermetabolic metastases in the right obturator node, anterior pelvic wall above, and adjacent to the bladder as well as multiple small liver metastases in the posterior aspect of the right lobe (Segment VII) and in the caudate lobe. Sharp delineation of small liver lesions with high contrast compared to normal liver without respiratory gating reflect the overall high image quality and high lesion contrast to background in the Biograph Vision images.

Hypermetabolic right obturator and liver metastases visualized with high contrast on ¹⁸F FDG PET/CT in a patient with operated ovarian carcinoma.

Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) ¹⁸ FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

Hypermetabolic right obturator and liver metastases visualized with high contrast on ¹⁸F FDG PET/CT in a patient with operated ovarian carcinoma.

Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) ¹⁸ FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

Hypermetabolic right obturator and liver metastases visualized with high contrast on ¹⁸F FDG PET/CT in a patient with operated ovarian carcinoma.

Examination protocol
Biograph Vision, 7.5 mCi (280 MBq) ¹⁸ FDG, 1 hour 49 minutes post-injection delay. CT: 140 kV, 16 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 220 x 220 matrix.

Small hypermetabolic foci in the right lobe of liver close to the diaphragm visualized with high contrast and minimal motion related blurring with ¹⁸F FDG PET/CT.

Clinical detail
A 69-year-old male with a history of operated colorectal carcinoma with suspected recurrence underwent ¹⁸F FDG PET/CT for restaging. A PET/CT was performed on Biograph Vision™. The images showed sharp delineation of small hypermetabolic metastasis in the right lobe of liver near the dome of diaphragm (Segment VII). Intense uptake in the abdominal wall is suggestive of metastatic deposit. Mildly increased uptake in mediastinal lymph nodes are possibly secondary to inflammation. High contrast of small liver metastases without significant motion related blurring even without respiratory gating reflects high overall image quality and increased lesion contrast to background in the Biograph Vision images.

Small hypermetabolic foci in the right lobe of liver close to the diaphragm visualized with high contrast and minimal motion related blurring with ¹⁸F FDG PET/CT.

Examination protocol
Biograph Vision, 7.3 mCi (270 MBq) ¹⁸F FDG, 1 hour 50 minutes post-injection delay. CT: 100 kV, 10 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

_{^* Indications and Important Safety Information.}

Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with ¹⁸F-Fluoroestradiol (FES).

Clinical detail
A 77-year-old female with a history of breast carcinoma treated with left mastectomy and chemo-radiotherapy presented with pain in the thoracic wall along with pleural effusion. The patient underwent ¹⁸F Fluoroestradiol (FES) PET/CT to assess presence of estrogen receptor (ER) positive metastases. A PET/CT was performed on Biograph Vision™. High resolution PET images show faint uptake in the left pleura suggestive of ER positive pleural thickening. The PET/CT images also sharply delineates physiological uptake in the gall bladder and biliary tract and intestine reflecting hepatobiliary clearance of tracer. Sharp definition of biliary tree with high contrast compared to background even at 440 x 440 matrix reconstructed resolution reflect the high overall image quality of Biograph Vision images.

Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with ¹⁸F-Fluoroestradiol (FES).

Examination protocol
Biograph Vision, 5.2 mCi (195 MBq) ¹⁸F FES, 1 hour 29 minutes post-injection delay. CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

_{^[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.}

Sharp visualization of physiological uptake in biliary tract, gall bladder, liver, and intestines in a patient with breast carcinoma without estrogen receptor positive metastases undergoing PET/CT imaging with ¹⁸F-Fluoroestradiol (FES).

Examination protocol
Biograph Vision, 5.2 mCi (195 MBq) ¹⁸F FES, 1 hour 29 minutes post-injection delay. CT: 100 kV, 13 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

_{^[a] The tracer used in this case is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries worldwide. Siemens does not make any claims regarding its use.}

Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in ¹⁸F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.

Clinical detail
A 79-year-old male with unknown clinical history. A PET/CT was performed on Biograph Vision™. High resolution PET images show sharp delineation of physiological uptake in the aortic walls, atrial walls, carotid, and subclavian vessels. Normal marrow uptake within vertebrae, ribs, and pelvis are well visualized. Physiological uptake in the gastric mucosa and intestines, with note made of sharply delineated descending colon. Sharp delineation of normal structures like rib and vessels with low background uptake reflect high overall image quality even at 440x440 matrix reconstructed resolution of Biograph Vision images.

Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in ¹⁸F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.

Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) ¹⁸F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

Sharp delineation of physiological uptake in vascular walls, marrow, and intestine with ¹⁸F FDG^* PET/CT
Physiological uptake in aortic walls, carotid and subclavian vessels as well as normal marrow uptake in the vertebrae, ribs and pelvis sharply delineated in ¹⁸F FDG PET/CT study on Biograph Vision™ reconstructed with high resolution at 440 x 440 matrix.

Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) ¹⁸F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in ¹⁸F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.

Clinical detail
70-year-old male. Though clinical history unknown, there are obviously multiple metastases as shown on PET/CT performed on the Biograph Vision™. High resolution PET images show multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae and soft tissue. Sharp delineation with high lesion contrast of small metastases in the vertebrae, pelvis, mediastinal nodes and soft tissue especially in the left thigh reflect the high image quality even at 440x440 matrix reconstructed resolution of the Biograph Vision images.

Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in ¹⁸F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.

Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) ¹⁸F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.

Multiple hypermetabolic metastases in the liver, mediastinal lymph nodes, vertebrae, and soft tissue sharply delineated in ¹⁸F FDG PET/CT study on Biograph Vision reconstructed with high resolution at 440 x 440 matrix.

Examination protocol
Biograph Vision, 8.2 mCi (305 MBq) ¹⁸F FDG, 1 hour 41 minutes post-injection delay. CT: 100 kV, 11 eff mAs. 32 x 1.2 mm collimation, PET: 7 beds 3 minutes/bed 440 x 440 matrix.